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A replication-defective mutant of herpes simplex virus 2 (HSV-2) was engineered by replacing the ICP8 gene of HSV-2
strain 186 with an ICP8–lacZ fusion gene from the herpes simplex virus 1 (HSV-1) HD-2 mutant strain. The resulting virus,
HSV-2 5BlacZ, is defective for growth in Vero cells but is capable of growth in a cell line that expresses HSV-1 ICP8. In
Vero cells, the mutant virus is defective for DNA synthesis but is able to express many viral proteins at levels similar to
those of wild-type virus, including several of the late kinetic class. SDS–PAGE and Western blot analysis demonstrated the
expression of glycoproteins B and D by 5BlacZ in Vero cells. Initial studies have shown that immunization with 5BlacZ
protects guinea pigs from intravaginal HSV-2 challenge. Immunized animals had less severe genital skin disease and
reduced replication of the challenge virus in the genital tract during primary infection and reduced episodes of recurrent
disease. Thus, HSV-2 ICP8 shows gene regulatory properties similar to those of HSV-1 ICP8, and this HSV-2 ICP8 mutant
virus shows a phenotype similar to those of HSV-1 ICP8 mutant strains. Replication-defective mutants of HSV-2 offer a
potential vaccine approach for immune intervention against HSV-2 genital disease and latent infection. q 1997 Academic Press
INTRODUCTION nomes. This novel phenotype of HSV-1 ICP8 mutants has
been exploited to provide replication-defective mutant
Productive infection by herpes simplex virus proceeds
viruses for vaccine strains that can express a broad
through a cascade of events in the order of immediate
spectrum of viral proteins, including late proteins, in the
early (IE) gene expression, early (E) gene expression,
absence of viral DNA replication. The HSV-1 ICP8 mutantviral DNA replication, and late (L) gene expression. The
d301 has been used to protect against lethal challengeexpression of E proteins requires the IE protein ICP4
infection (Nguyen et al., 1992) and against establishmentand, in some cases, the IE ICP27 protein. The expression
of latent infection in a mouse corneal challenge modelof viral late proteins requires IE proteins ICP4 and ICP27
(Morrison and Knipe, 1994, 1996). The lack of viral DNAand viral DNA replication. Seven HSV-1 gene products,
synthesis in cells infected with a vaccine virus wouldincluding the viral DNA polymerase (UL30), the polymer-
provide greater safety in preventing viral DNA exposurease accessory factor (UL42), the origin-binding protein
to the host and the cellular mutagenic events that have(UL9), the single-stranded DNA-binding protein (UL29 or
been associated with viral DNA replication, including cel-ICP8), and the helicase– primase complex (UL5, UL8, and
lular DNA amplification (Heilbronn and Zur Hausen, 1989)UL52) are required for viral DNA replication (Challberg,
and chromosomal aberrations (Chenet-Monte et al.,1986; Knipe, 1989; Weller, 1991). The ICP8 protein also
1986).plays a role in regulating viral gene expression in that
Herpes simplex virus 2 (HSV-2) is responsible for mostICP8 ts mutants show overexpression of viral gene prod-
cases of genital herpes disease. Pregnant women withucts at the nonpermissive temperature (Godowski and
genital herpes are at risk of transmitting the virus toKnipe, 1985, 1986), and a dominant mutant form of ICP8
their newborns at parturition, which may result in severe,can inhibit late gene transcription (Chen and Knipe, 1996;
potentially fatal neurologic or disseminated disease inGao and Knipe, 1991). A notable phenotype of viral mu-
the newborn. Several vaccines against HSV-2, includingtants bearing ts and deletion mutations in the ICP8 gene
subunit glycoprotein preparations (Meignier et al., 1987;is the expression of substantial amounts of late viral
Mertz et al., 1990; Stanberry et al., 1987), have beenproteins in the absence of viral DNA replication. There-
tested for their ability to prevent genital disease in animalfore, HSV-1 ICP8 plays a role in suppressing transcription
models as well as in clinical trials. In addition, viral vec-of viral late genes from input or parental viral DNA ge-
tors such as human adenovirus expressing HSV-2 glyco-
protein B (gB) (McDermott et al., 1989) and vaccinia virus
1 To whom correspondence and reprint requests should be ad- expressing HSV-1 or HSV-2 glycoprotein D (gD) (Aureliandressed at Department of Microbiology and Molecular Genetics, Har-
et al., 1991) have been tested in mice and, in the lattervard Medical School, 200 Longwood Avenue, Boston, MA 02115. Fax:
(617) 432-0223. E-mail: dknipe@warren.med.harvard.edu. case, in guinea pigs also. Recombinant HSV-1 viruses
1
0042-6822/97 $25.00
Copyright q 1997 by Academic Press
All rights of reproduction in any form reserved.
AID VY 8564 / 6a34$$$401 04-28-97 21:54:10 viral AP: Virology
2 DA COSTA ET AL.
expressing HSV-2 glycoproteins D, E, G, and part of I which were prepared as described by Stanberry (1982).
In experiments in which inactivated virus was used tohave been tested in several animal models including
guinea pigs and owl monkeys (Meignier et al., 1988a, immunize animals, virus stocks were inactivated with b-
propiolactone, resulting in a 5-log reduction in virus titer.1988b, 1990). This vaccine has also been tested in clini-
cal trials, the results of which have been reviewed re-
Plasmidscently (Stanberry, 1996). In addition, an HSV-2 gH gene
deletion mutant virus that undergoes a single round of
Plasmid pICP8–lacZ was constructed by digesting
replication in infected cells has been tested in guinea
HSV-1 HD-2 DNA with BamHI and cloning the largest
pigs for its ability to protect against an HSV-2 challenge
fragment, approximately 12.2 kbp in size, into the BamHI
(Boursnell et al., 1997). More recently, nucleic acid vac-
site of plasmid pNEB193 (New England Biolabs, Beverly,
cines expressing HSV-2 gD have been evaluated in mice
MA). This HD-2 BamHI fragment extends from upstream
or guinea pig models of genital herpes (Bourne et al.,
of the ICP8 promoter (BamHI V/R junction of HSV-1; bp
1996; Ghiasi et al., 1995; Kriesel et al., 1996).
62,653 from the sequence of McGeoch et al. (1988)) to
HSV-2, although less well studied than HSV-1, is highly
downstream of the gB gene (BamHI G/E* junction; bp
homologous to HSV-1 and shows many common gene
52,588 (McGeoch et al., 1988)). Following transformation
regulatory patterns. The HSV-2 ICP8 is also required for
into bacterial cells, white colonies selected on medium
viral DNA synthesis (Spang et al., 1983) and can substi-
containing the chromogenic substrate X-Gal were
tute for HSV-1 ICP8 (Conley et al., 1981; Morse et al.,
screened for the presence of the insert. The identity of
1978). However, nothing is known about the effects of
desired clones was confirmed by restriction endonucle-
HSV-2 ICP8 on viral gene expression. To determine if
ase analysis. Plasmid pEH60 (Spang et al., 1983), which
HSV-2 ICP8 exerted regulatory effects similar to those of
contains an EcoRI–HindIII DNA fragment from HSV-2
the HSV-1 protein and to determine if an HSV-2 ICP8
strain 186 syn/-1 from approximately 0.31–0.40 map
mutant virus could provide a safe, live virus vaccine
units, that was cloned into pBR322 was used to rescue
against genital herpes, we have engineered an HSV-2
the HSV-2 ICP80 mutant, 5BlacZ, constructed in this
ICP8 mutant virus, characterized the effect of HSV-2 ICP8
study. All restriction enzymes were obtained from New
on viral gene expression, and conducted initial tests of
England Biolabs.
this mutant virus for its ability to protect guinea pigs
against vaginal HSV-2 challenge. We selected the guinea Marker transfer using cotransfection
pig model because it has been used to evaluate several
vaccine candidates that are currently in clinical trials Viral recombinants were isolated by homologous re-
combination in cells cotransfected with infectious HSV-and because the model mimics genital HSV infection in
humans using a natural route of inoculation (intravaginal) 2 DNA and cloned segments of viral DNA as described
previously (Spang et al., 1983). The method used was ato produce a self-limited primary infection which results
in establishment of latency and subsequent spontaneous modification (Knipe et al., 1979; Ruyechan et al., 1979) of
the calcium phosphate coprecipitation method (Grahamrecurrent infections (Stanberry, 1991).
and Van der Eb, 1973). Infectious HSV-2 viral DNA was
purified by sodium iodide density gradient centrifugationMATERIALS AND METHODS
(Walboomers and ter Schegget, 1976). Cloned viral DNA
Cells and viruses
sequences for cotransfection were cleaved from recom-
binant plasmids, isolated by gel electrophoresis, purifiedVero (ATCC, Rockville, MD) and S2 cells which contain
the HSV-1 ICP8 gene were grown and maintained as by phenol–chloroform extraction and ethanol precipita-
tion, and resuspended in TE buffer. Alternatively, recom-described previously (Gao and Knipe, 1989). The HSV-1
ICP80 mutant virus strain HD-2, which contains the lacZ binant plasmids were linearized outside of the HSV se-
quences and purified. The cloned sequences were co-coding sequences fused to the ICP8 ORF, has been de-
scribed previously (Gao and Knipe, 1989). The wild-type transfected with 1 mg of infectious viral DNA at
plasmid:viral DNA molar ratios ranging from 5:1 to 30:1HSV-2 strain 186 syn/-1 virus, used as the parental wild-
type (wt) HSV-2 strain, was originally isolated as a non- into subconfluent S2 cell monolayers in 25-cm2 flasks
(Corning Inc., Corning, NY). Each flask was transfectedsyncytial plaque (Spang et al., 1983) from HSV-2 strain
186 (Rawls et al., 1968) stock kindly provided by P. Schaf- with a total of 16 mg of DNA with salmon sperm DNA
serving as carrier. After viral CPE was apparent, infectedfer. The HSV-2 strain MS (Stanberry et al., 1982) was
used as the vaginal challenge virus in immunized and cell lysates were prepared by the addition of 0.5 vol of
sterile reconstituted milk (nonfat powdered milk; Carna-control animals. All ICP80 mutant viruses were grown
on the complementing S2 cell line. The wild-type HSV-2 tion Co., Los Angeles, CA), three cycles of freeze–thaw-
ing, and sonication. The transfected cell lysate containingstrains 186 syn/-1 and MS were grown on Vero cells
and primary rabbit kidney (PRK) cells, respectively. Virus the progeny virus was plated in 10-fold dilutions on con-
fluent S2 or Vero cell monolayers in 6-well trays (Corn-stocks were prepared and stored as described by Mor-
rison and Knipe (1996), except for challenge virus stocks ing). The infected monolayers were overlaid with 199–
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1% CS medium (199 medium containing 1% calf serum) were resuspended in a 0.5% (w/v) solution of trypan blue
in phosphate-buffered saline and counted in a hemocy-plus 0.1% human Ig (Massachusetts Public Health Bio-
logic Labs, Boston, MA) and incubated at 377. Plaque tometer. Nonviable cells were enumerated by dye up-
take, and their numbers were expressed as a percentageformation was usually observed within 2 days after plat-
ing. For in situ detection of b-galactosidase expression, of the total cell count.
the infected cell monolayers were then washed twice
Analysis of viral proteinswith 199–1% CS medium and overlaid with a 1:1 mix of
21 199–1% CS medium and 1% agarose containing 300 The pattern of gene expression in virus-infected cells
mg/ml X-Gal (Boehringer Mannheim, Indianapolis, IN). was examined by isotopic labeling of proteins and SDS–
Plaques formed by viruses expressing b-galactosidase PAGE. Vero cells were infected with virus at an m.o.i. of
showed blue staining within 6–12 hr. 20 or were mock-infected. Infections were carried out
either in the presence or in the absence of a viral DNA
Southern hybridization synthesis inhibitor, phosphonoacetic acid (PAA), at a
concentration of 400 mg/ml. Virus or mock-infected cellsTo isolate viral genomic DNA, confluent cell mono-
were pulsed with [35S]methionine, [35S]cysteine (Tran35S-layers in tissue culture flasks were infected with virus at
label, ICN, Irvine, CA) in methionine-free Eagle’s modifiedan m.o.i. of 1 and incubated for 2 to 3 days at 347. When
MEM medium (ICN) for 30 min (2 ml, 15 mCi/ml) andinfected cells became loosely attached to the substrate,
harvested at various times postinoculation. Cell lysatesthey were shaken off, transferred to 50-ml polypropylene
were subjected to SDS–PAGE in 9.25% gels. Followingcentrifuge tubes (Corning), and collected by centrifuga-
electrophoresis, gels were fixed, stained with Coomassietion at 300 g, 47 in an IEC centrifuge (Model CRU-5000,
blue, dried, and exposed to Kodak SB-5 film for autoradi-Needham Heights, MA). The cells were gently lysed in
ography. To quantify the levels of viral proteins expressedbuffer (100 mM Tris–Cl, pH 8.0; 10 mM EDTA, 1% SDS),
in infected cells, the autoradiograms were scanned usingand the lysate was digested with Proteinase K (200 mg/
an LKB Bromma Ultrascan XL Laser densitometer, andml). Viral DNA was isolated using sodium iodide gradi-
peak areas representing specific viral protein bandsents, dialyzed against TE buffer, quantitated by UV spec-
were determined.trophotometry, enzymatically restricted with EcoRI and
KpnI, SalI, or XhoI, resolved by electrophoresis in 0.7%
Immunoblotsagarose gels, and transferred to nylon membranes (Ny-
tran; Schleicher and Schuell, Keene, NH) for Southern The levels of expression of specific viral glycoproteins
hybridization. The membranes were probed with linear- were determined by immunoblot assay. Infected cell ly-
ized, 32P-labeled pICP8–lacZ plasmid DNA. Labeling with sates were resolved by electrophoresis using a mini pro-
[a32P]dCTP (New England Nuclear, Boston, MA) was per- tein gel apparatus (Bio-Rad, Richmond, CA), electroblot-
formed using a random-primer labeling kit (Boehringer ted onto nitrocellulose membranes, and probed for viral
Mannheim, Indianapolis, IN). glycoproteins gB and gD. Rabbit polyclonal sera R1161
(provided by Dr. R. Courtney) and R-45 (provided by Dr.
DNA replication G. Cohen and Dr. R. Eisenberg) were used as primary
antibodies to detect glycoproteins gB and gD, respec-To examine viral DNA replication, Vero cells were in-
tively. Goat anti-rabbit alkaline phosphatase-conjugatedfected with wild-type virus or 5BlacZ at an m.o.i. of 20 or
secondary antibody (Promega, Madison, WI) was used towere mock-infected. Cells were overlaid with 199–1%
detect the immune complexes. The enzymatic substratesCS medium and incubated at 377. DNA was labeled from
nitro blue tetrazolium (NBT) and 5-bromo-4-chloro-3-indo-3 to 7 hr postinoculation by changing the overlay medium
lylphosphate (BCIP) were used in the reaction to detectto 199–1% CS containing 25 mCi/ml [3H]thymidine (New
alkaline phosphatase activity as recommended by theEngland Nuclear). Cells were harvested at 7 hr postinoc-
supplier (Promega).ulation, and total DNA was isolated as described by
Challberg (1986). Equivalent amounts of labeled DNA
Animalswere digested with BamHI and resolved by electrophore-
sis in 0.5% agarose gels. The gel was fluorographed Female Hartley guinea pigs were obtained from
(Entensify, New England Nuclear), dried, and exposed to Charles River Breeding Laboratories (Wilmington, MA)
film (Kodak XAR) at 0807 for 3 days. and housed under AAALAC-approved conditions. All pro-
cedures and protocols were approved by Children’s Hos-
Cell viability pital Research Foundation Animal Care and Use Commit-
tee (Cincinnati, OH).The viability of infected cells was assayed by trypan
blue exclusion (Fuller et al., 1995). Briefly, confluent Vero
Immunization studiescell monolayers in T25 flasks were infected with wild-
type virus or 5BlacZ at an m.o.i. of 5 or mock-infected Female guinea pigs were randomized into three
groups of 12 animals each and were immunized with 0.5and harvested at 24, 48, or 72 hr postinoculation. Cells
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ml of a suspension containing 107 PFU of 5BlacZ by
subcutaneous injection on the back or into the two rear
footpads or were left unimmunized. In other experiments,
animals were immunized with 5BlacZ either vaginally
with live virus or in the rear footpads with live or inacti-
vated virus. Viral challenge was performed on Day 33
postimmunization. The animals were inoculated with vi-
rus by rupturing the vaginal closure membrane with a
moistened calcium alginate-tipped swab (Calgiswab 3,
Spectrum Labs, Los Angeles, CA) and instilling 0.1 ml of
a virus suspension containing 5 1 105 PFU of HSV-2
strain MS into the vaginal vault using a plastic catheter
(Abbocath, Abbott Labs, North Chicago, IL). To maximize
the number of animals infected, the inoculation proce-
dure was repeated 30 min later. Vaginal swab samples
were collected on Days 1, 2, 3, 5, 7, and 10 postinocula-
FIG. 1. Map of pICP8-lacZ plasmid. This plasmid was constructedtion and stored frozen at 0707 until assayed for the pres-
by cloning the largest BamHI fragment (approximately 12.2 kbp) fromence of virus by titration on primary rabbit kidney cells.
HD-2 virus DNA into the BamHI site of the plasmid vector pNEB193.Guinea pigs were evaluated daily and the severity of
The vector is indicated by the light stippled area. The ICP8 gene is
primary genital skin disease was quantified using a le- indicated by the black arrow. The lacZ coding sequences are indicated
sion score scale described previously (Stanberry et al., by the horizontal bars. The UL28 gene is indicated by the hatched
arrow. The gB gene is indicated by the dark stippled arrow. The posi-1982). Primary genital skin disease was defined as any
tions of several enzyme restriction sites are as indicated. Arrowheadsprimary episode clinical disease beginning before Day
indicate the 3*-termini of the genes.10 postinoculation. Following recovery from primary in-
fection, animals were examined daily from Days 15 to 42
postinoculation for evidence of spontaneous recurrent plaques appeared blue. Several independently isolated
herpetic disease (Stanberry et al., 1985a). blue plaques were screened for the presence of the ICP8
mutation by the ability to grow on the S2 complementing
RESULTS cell line and the failure to grow on Vero cells. Two such
isolates, 5BlacZ and 20BlacZ, were plaque-purified thriceConstruction of an HSV-2 ICP8 gene mutant
and their genomes were checked by Southern analysis.
To introduce a mutation into the HSV-2 ICP8 gene, we
chose to replace the HSV-2 ICP8 gene with an ICP8– Analysis of the mutant viral genomes
lacZ gene fusion that we had previously engineered in
the HSV-1 HD-2 viral strain (Gao and Knipe, 1989). The The growth of 5BlacZ on S2 cells, which express ICP8
upon HSV infection and complement the growth of ICP8feasibility of this approach was suggested by the exten-
sive homology between the HSV-1 and HSV-2 genomes mutant viruses, provided the initial evidence that the mu-
tation in 5BlacZ was in the ICP8 gene. To confirm thatand the previous ease of isolation of intertypic recombi-
nants in general (Marsden et al., 1978; Morse et al., 1978) the ICP8 gene was mutated in 5BlacZ, we performed
Southern blot analysis on viral DNA from 5BlacZ, its sib-and around the ICP8 gene in particular (Conley et al.,
1981). To this end, we cloned a BamHI DNA fragment ling 20BlacZ, the HSV-1 HD-2 strain, and the parental
HSV-2 186 wt strain. Viral DNA was digested with EcoRIencompassing the ICP8–lacZ gene fusion from HD-2 vi-
rus DNA into plasmid vector pNEB193 to generate plas- and KpnI, resolved by gel electrophoresis, transferred to
nylon membranes, and probed with a 32P-labeled BamHImid pICP8–lacZ (Fig. 1). Because this BamHI fragment
contains other viral genes including the gB gene of HSV- DNA fragment from HD-2 shown in the second line of
Fig. 2D. The probe hybridized with two fragments of 6.41, a 6.4-kbp KpnI subfragment containing the ICP8–lacZ
gene fusion but excluding the gB gene was isolated and and 7.8 kbp (Fig. 3, lane 1) of HSV-2 wt DNA, which map
as shown in Fig. 2D. In contrast, the probe hybridizedused to construct the HSV-2 ICP8 mutant virus (Fig. 1).
This fragment, which extends from 233 bp downstream strongly with four fragments of 1.9, 3.6, 2.8, and 4.7 kbp
of HD-2 DNA (Fig. 3, lane 4), which map as shown inof the ICP8 ATG initiation codon to approximately 1.3 kbp
upstream of the gB gene promoter, was cotransfected Fig. 2D. With 5BlacZ and 20BlacZ DNA, the probe hybrid-
ized to new fragments of 5.5 and 2.9 kbp as well as towith HSV-2 186 syn/-1 viral DNA into S2 cells. From the
progeny viruses, we isolated viruses that formed blue a 7.8-kbp fragment similar to that of HSV-2. The new
fragments in 5BlacZ and 20BlacZ were consistent withplaques under an X-Gal overlay and contained the ICP8–
lacZ gene fusion inserted into the ICP8 gene (Fig. 2). In a recombinational event inserting the ICP8– lacZ gene
fusion into the 6.4-kbp fragment of HSV-2 or within thethe initial screen for viruses that formed blue plaques
under the X-Gal overlay, approximately 1 in every 103 ICP8 gene (Fig. 2D). No other bands were observed with
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FIG. 2. Map of the 5BlacZ genome. (A) The genome structural arrangement of HSV DNA. The rectangles represent repeat regions of the genome,
and the lines connecting them represent unique sequences. (B) A KpnI restriction map of HSV-2 strain HG52 (Davison et al., 1981). (C) The HD-2
ICP8 –lacZ insert within the KpnI M fragment of 5BlacZ. The vertical bars represent the KpnI boundaries of fragment M. The thin and thick horizontal
lines represent HSV-1 and HSV-2 DNA, respectively. The lacZ coding sequences within ICP8 are shown as a rectangle. The arrow depicts the
direction of transcription. (D) An EcoRI–KpnI map of HSV-1 HD-2, HSV-2 5BlacZ, and HSV-2 wt DNA oriented from left to right as 0.43 to 0.31 map
units (inverted from the prototype orientation shown in A and B). The restriction sites are marked by vertical lines and labeled either E or K for
EcoRI or KpnI, respectively. The lengths of fragments in kbp are indicated between restriction sites. The arrow represents the ICP8– lacZ ORF. The
hatched rectangles in the 5BlacZ map represent the cross-over region between the pICP8–lacZ KpnI fragment and the HSV-2 wt genome. The map
position of the ICP8–lacZ BamHI fragment used as the probe in Southern analysis is shown as a stippled bar.
5BlacZ or 20BlacZ (Fig. 3, lanes 2 and 3), providing evi- the lower limit for the titer of 5BlacZ on Vero cells (Table
1) was calculated from the lowest dilutions at whichdence that the lacZ sequences were inserted only within
the ICP8 gene locus. Other digests with EcoRI and SalI plaques could have been detected, and the efficiency of
plating of 5BlacZ on Vero cells compared to S2 cells wasor EcoRI and XhoI also confirmed this mapping of the
insertional mutation in the ICP8 gene (Da Costa and calculated to be 3 1 1007. In contrast, wild-type virus
formed plaques equally well in Vero cells and in S2 cellsKnipe, results not shown).
(Table 1).
Viral DNA synthesis. HSV-1 ICP8 is an essential genePhenotype of 5BlacZ
product for viral DNA replication. To examine the ability
HSV-1 ICP8 mutant viruses grow only on a comple- of the HSV-2 ICP8 mutant virus to replicate its DNA,
menting cell line and do not replicate viral DNA in normal [3H]thymidine-labeled DNA was isolated from Vero cells
cells (Gao and Knipe, 1989; Orberg and Schaffer, 1987). infected with either wt HSV-2 or 5BlacZ or mock-infected
The HSV-2 ICP8 mutant isolated in this study, 5BlacZ, and enzymatically restricted and resolved in agarose
was also examined for its phenotypic properties. gels (Fig. 4). From cells infected with wt virus, a series
Growth properties. The 5BlacZ mutant virus formed of viral DNA bands was labeled (Fig. 4, lane 1), consistent
plaques and grew to titers comparable to those of wt with viral DNA synthesis, while a smear of bands was
virus on S2 cells but did not form plaques on Vero cells labeled in mock-infected cells due to cellular DNA repli-
(Table 1). At low dilutions, a general cytopathic effect cation (Fig. 4, lane 3). In contrast, no viral DNA bands
was observed on Vero cells, preventing detection of any were labeled in cells infected with 5BlacZ (Fig. 4, lane
2), indicating that no viral DNA synthesis occurred inreplication-competent virus at these dilutions. Therefore,
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FIG. 3. Southern blot analysis of recombinant viral genomes. Viral
DNA was isolated and restricted with EcoRI and KpnI. Digests were FIG. 4. Measurement of viral DNA replication. Vero cells were in-
resolved by electrophoresis in 0.7% agarose gels, blotted onto nylon fected with wt HSV-2 186 syn/-1 (lane 1) infected with HSV-2 ICP80
membranes, and probed with a [32P]dCTP-labeled pICP8–lacZ BamHI mutant 5BlacZ (lane 2), or mock-infected (lane 3) and were labeled
fragment. Lane 1, wt HSV-2 186 syn/-1; lane 2, HSV-2 ICP80 mutant with [3H]thymidine from 4 to 7 hr post-infection. Total DNA was isolated,
5BlacZ; lane 3, HSV-2 ICP80 mutant 20BlacZ; lane 4, HSV-1 ICP80 equivalent amounts of each DNA sample (4 mg) were digested with
mutant HD-2. Sizes of DNA fragments in kbp are indicated at the right BamHI, and the fragments were resolved by electrophoresis in a 0.5%
of the figure. agarose gel. A fluorogram of the dried gel is shown.
gene, we used marker rescue to restore a wild-type ICP8these cells. Furthermore, cell DNA labeling was greatly
reduced in these mutant virus-infected cells (Fig. 4, lane gene into the 5BlacZ genome. The ICP8 mutation in
5BlacZ was rescued with plasmid pEH60, which contains2). Therefore, HSV-2 ICP8 is required for viral DNA syn-
thesis but not for the bulk of the shut-off of host DNA the ICP8 gene of the parental HSV-2 186 syn/-1 strain.
Mutant virus was rescued at a frequency of betweensynthesis in infected cells. Nevertheless, we cannot rule
out the possibility that ICP8 is required for a small part 0.04 and 2%. One of the rescuants, 5BR, was chosen for
characterization. The 5BR strain grew equally well onof the shut-off of host DNA synthesis.
Gene expression. Initial comparisons of protein ex- Vero and S2 cells (Table 1). Southern blot analysis of the
rescued virus and wt HSV-2 virus using the HSV-1 ICP8pression by 5BlacZ and wild-type virus showed some
differences in levels and patterns of protein expression plasmid p8B-S (Gao and Knipe, 1989) as probe revealed
identical hybridization patterns for the two viruses (re-(results not shown). To prove that the protein expression
phenotype of 5BlacZ was due to the mutation in the ICP8 sults not shown).
TABLE 1
Plaque Formation of 5BlacZ, Rescued, and Wild-Type Virus on Vero and S-2 Cells
Viral titer (PFU/ml)a
Virus Genotype Vero cells S2 cells
186 syn/-1b wt 3.2 1 108 3.1 1 108
5BlacZ lacZ insertion in ICP8 102 8.9 1 108
5BRc wt ICP8 gene restored in 5BlacZ 9.3 1 108 9.9 1 108
a Dilutions of a stock of each virus were plated in duplicate on both Vero cells and S2 cells in T25 flasks.
b Wild-type parental strain from which 5BlacZ was derived.
c Rescued 5BlacZ.
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TABLE 2
Levels of Late Protein Synthesis in Cells Infected
with Mutant and Rescued Viruses
Viral proteina
Virus ICP5 gB ICP15 ICP25
5BR 142 (100) 100 (100) 29 (100) 29 (100)
5BlacZ 61 (43) 67 (67) 38 (131) 27 (93)
5BR / PAA 18 (13) 40 (40) 13 (45) 9 (31)
5BlacZ / PAA 36 (25) 51 (51) 23 (79) 23 (79)
a Numbers represent units of protein at 9 hr postinoculation as deter-
mined by densitometry of autoradiogram bands. Numbers in parenthe-
ses represent the percentage of 5BR values in cells infected in the
absence of PAA.
control cells (0PAA). Thus, although the mutant virus did
not replicate its genome, it expressed gB, an important
target for anti-HSV immunity, at levels nearly equivalent
to those of the rescued virus.
Levels of accumulation of glycoproteins gB and gD.
The above results using analysis of labeled protein
FIG. 5. Polypeptide profiles of Vero cells infected with the HSV-2 bands resolved by SDS–PAGE indicated that 5BlacZ ex-
ICP80 mutant 5BlacZ (lanes 1, 4, 7, and 10), rescued strain 5BR (lanes pressed significant levels of late proteins, in particular
2, 5, 8, and 11) or wt HSV-2, 186 syn/-1 (lanes 3, 6, 9, and 12), or mock- gB, at 9 hr postinoculation. To ensure the specificity of
infected (lanes 13 and 14) either in the absence or in the presence of
detection of the viral glycoproteins, we used Western400 mg/ml PAA as indicated. Cells were labeled for 30 min prior to
blot analysis to determine the levels of accumulation ofbeing harvested at 5 hr postinfection (lanes 1–6) or 9 hr postinfection
(lanes 7–14). The migration positions of some representative viral poly- the gB and gD glycoproteins (Fig. 6). Comparisons of
peptides are indicated on the left. equivalent amounts of lysates revealed that cells infected
with 5BlacZ accumulated gB (Fig. 6, lanes 5–8) and gD
(Fig. 6, lanes 1–4) at levels only slightly lower than thoseWe then examined the patterns of protein synthesis in
in cells infected with wt virus. Therefore, 5BlacZ ex-Vero cells infected with the mutant 5BlacZ, the rescuant
pressed significant levels of authentic gB and gD al-5BR, or wild-type virus in the presence and in the ab-
though it did not replicate viral DNA.sence of PAA, a specific inhibitor of viral DNA synthesis.
At 5 or 9 hr postinoculation, we labeled the cultures with
[35S]methionine and [35S]cysteine for 30 min. The cells
were harvested, and infected cell-lysates were prepared
and resolved by SDS–PAGE (Fig. 5). Examination of auto-
radiograms revealed that major proteins of all kinetic
classes were expressed by 5BlacZ at levels similar to or
slightly less than those expressed by the wild-type paren-
tal virus (Fig. 5), including g genes such as ICP5, gB,
and ICP15. Densitometric measurements of the band in-
tensities of the late gene products at 9 hr postinoculation
revealed that 5BlacZ expressed late proteins at 25–79%
of the levels of the rescued virus in cells infected in the
absence of PAA (Table 2). When PAA was added to all
cultures to inhibit viral DNA synthesis in both mutant and
rescued-mutant infected cultures, 5BlacZ expressed late FIG. 6. Western blot analysis of gB and gD in infected cell lysates.
proteins at levels similar (gB) to or 2- to 2.5-fold greater Proteins from 5BlacZ- (lanes 1, 2, 5, and 6) or HSV-2 wt- (lanes 3, 4, 7,
and 8) infected cell lysates were electroblotted from SDS–polyacryl-(ICP5, ICP15, ICP25) than the levels expressed by the
amide gels onto nitrocellulose membranes and probed with either anti-rescued virus (Table 2). Therefore, similar to HSV-1 ICP8,
gD (lanes 1–4) or anti-gB (lanes 5–8) antibody. Lanes 1, 3, 5, and 7HSV-2 ICP8 decreases late gene expression in the ab-
were loaded with 20 ml of cell lysate and lanes 2, 4, 6, and 8 were
sence of viral DNA synthesis. Also, relevant to the use loaded with 40 ml. Arrowheads indicate the specific glycoprotein bands.
of the mutant virus for immunization studies, 5BlacZ ex- The molecular weight markers are in lane 9 with the corresponding
weights shown on the right.pressed gB at 67% of the level of the rescued virus in
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infectious progeny in those cells, we investigated its abil-
ity to elicit protective immunity against HSV-2 genital dis-
ease in a guinea pig model. Animals were immunized
with 5BlacZ by one of three routes: subcutaneous injec-
tion in the back, subcutaneous injection in the rear foot-
pad, or intravaginal immunization. Immunizations were
performed with either live or inactivated virus stocks.
Following immunization, all animals were challenged
with wt HSV-2. Two challenge stocks of the same HSV-
2 MS strain were used: one a high-virulence stock used
mainly to study primary disease and the other a low-
virulence stock used mainly to study recurrent disease.
Effects of immunization on primary infection and dis-
ease. Three groups of 12 female Hartley guinea pigs
were immunized with a single dose of 107 PFU of 5BlacZ
virus administered subcutaneously in the footpads or in
the back, or left untreated. At Day 33 postimmunization,
the animals were challenged intravaginally with a high-
virulence stock of HSV-2 strain MS to achieve an efficient,
FIG. 7. Loss of cell viability by infected cells. Vero cells were infected synchronous primary vaginal infection (Stanberry, 1982)
with wt HSV-2 or 5BlacZ at an m.o.i. of 5 or mock-infected and harvested and evaluated daily for signs of disease (Table 3). The
at 1, 2, or 3 days postinoculation. Loss of cell viability was determined amount of virus shed in the genital tract of all animals
by trypan blue dye uptake and expressed as a percentage of the total
was also determined from vaginal swabs taken at variouscell count.
times postinoculation (Fig. 8). A single immunization with
5BlacZ afforded guinea pigs significant protection from
Viability of cells infected with mutant virus
genital herpes. In contrast to the control group in which
A potential concern about the use of a replication- 11 of 12 animals exhibited lesions, only 3 of 12 animals
defective mutant virus as a vaccine is that the infected immunized in the footpad developed the cutaneous le-
cell might survive and the mutant virus could establish sions characteristic of primary genital herpes, and dis-
a persistent infection in the host. We therefore examined ease in these animals was very mild. In addition, 6 of
the fate of cells infected with the mutant virus. Vero cells
were infected with either wt HSV-2 or 5BlacZ and har-
vested at 1, 2, or 3 days postinoculation. Loss of cell TABLE 3
viability was assessed by uptake of trypan blue and ex-
Effect of Subcutaneous and Footpad Inoculation of 5BlacZ Mutantpressed as a percentage of total cell counts. Infection
Virus on Primary and Recurrent Genital Herpes Following Intravaginalwith virus resulted in a 50 to 60% reduction in total cell
HSV-2 Challenge
counts by Days 1 and 2 and an almost 80% decrease by
Day 3 compared to uninfected cells (results not shown). Primary genital Recurrent genital
skin disease skin diseaseThe number of nonviable cells as assessed by trypan
Immunizationblue exclusion was expressed as a percentage of total
group Number a Severity b Number ccell counts for wt HSV-2, 5BlacZ, or mock-infected cells
(Fig. 7). Infection of cells with either virus resulted in a Untreated 11/12 8.4 { 0.48 6/7
2- to 5-fold increase in the percentage of nonviable cells Subcutaneous 6/12d 4.50 { 0.52e 7/12
Footpad 3/12f 1.0 { 0.29e,g 5/11by Days 1 and 2 and a 10-fold increase by Day 3, at
which time 100% of infected cells were nonviable. Over
a Number of animals with clinical disease/number of animals inthe same 3-day period, the percentage of nonviable cells
which virus could be isolated from the genital tract.among the uninfected controls remained at approxi- b Mean { SE. Severity measured as the area under the lesion score
mately 10%. Thus, it is clear that, despite the defect in curve calculated using only symptomatic animals.
its ability to replicate in Vero cells, 5BlacZ is still able to c Number of animals with recurrent disease/number of infected ani-
mals which could be assessed for recurrences from Days 15 to 42kill cells at a level comparable to wild-type virus. Like
postinoculation.wt virus infection (Leopardi and Roizman, 1996), cells
d P  0.07 compared to untreated controls (Fisher’s two-tail exactinfected with 5BlacZ appeared to die from necrosis in
test).
that cellular DNA fragmentation was not observed (re- e P  0.01 compared to untreated controls (Bonferroni correction
sults not shown). ANOVA).
f P  0.003 compared to untreated controls (Fisher’s two-tail exactImmunization studies with 5BlacZ
test).
Given the ability of 5BlacZ to express nearly wild-type g P 0.05 compared to subcutaneous animals (Bonferroni correction
ANOVA).levels of gB and gD in normal cells but not produce
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TABLE 4
Effect of Prophylactic Vaginal and Footpad Inoculation of 5BlacZ




group Number a All Symptomatic
Untreated 15/15 6.3 { 0.8 6.3 { 0.8
Vaginal 4/10c 1.2 { 0.6d 2.9 { 0.8
Footpad ‘‘inactive’’ 4/10e 0.4 { 0.2d 2.5 { 0.5
Footpad ‘‘live’’ 0/15e 0 { 0d 0 { 0
a Number of animals with symptomatic primary genital skin disease/
number inoculated.
b Mean { SE. Severity measured as area under the lesion score-
day curve.
c P  0.005.
d P  0.01 by ANOVA with Bonferroni correction.
e P  0.00001.
FIG. 8. Virus shedding in the genital tract after HSV-2 challenge. recurrent disease in a second experiment, a less virulent
Guinea pigs were left untreated or immunized with 5BlacZ by either stock, HSV-2 strain MS, than had been used in the initial
the footpad or the subcutaneous route. Following a vaginal challenge study of primary disease was used to challenge animals.
with HSV-2 strain MS, animals were swabbed to determine levels of
Prior to challenge, groups of guinea pigs were immu-virus shed in the genital tract. Samples were collected on Days 1, 2,
nized with two doses of 107 PFU 5BlacZ intravaginally or3, 5, 7, and 10 postinoculation and titrated on primary rabbit kidney
cells. Mean viral titers are presented as log10 PFU/ml. in the footpad or with an equivalent amount of virus that
had been inactivated by 5 logs with b-propiolactone. Im-
munization with 5BlacZ provided significant protection
12 subcutaneously immunized animals developed skin
against disease caused by primary infection as mea-
lesions, and the severity of disease was significantly re-
sured by the number and severity of lesions compared
duced compared to unimmunized controls. Thus, protec-
to the untreated controls (Table 4). None of the 15 ani-
tion from disease by subcutaneous immunization was
mals that received an inoculation of live virus via the
less than that achieved with footpad immunization. Al-
footpad developed primary genital skin disease com-
though immunization with 5BlacZ protected animals from
pared to 4 of 10 animals that received inactivated virus
primary genital herpes, 12 of 23 immunized animals de-
by the same route that did develop primary disease. Most
veloped recurrent genital herpes, indicating that a single
importantly, the number of animals showing recurrent
immunization elicited only partial protection from estab-
infections was significantly reduced by footpad immuni-
lishment of latent infection with this dose of high-viru-
zation (Table 5), and the frequency of recurrences was
lence challenge virus.
To examine the effects of immunization on viral shed-
TABLE 5ding in the genital tract, all animals were swabbed on
Days 1, 2, 3, 5, 7, and 10 postchallenge, and titers of Effect of Prophylactic Vaginal and Footpad Inoculation of 5BlacZ
Mutant Virus on Recurrent Genital Herpes Following Intravaginalvirus shed in the genital tract were determined by assay
HSV-2 Challengeon primary rabbit kidney cells. Virus was recovered from
vaginal swab specimens of all animals at Day 1, indicat-
Frequency b
ing that the vaccine did not protect against infection. Immunization
However, by Day 2, there was a 10-fold decrease in virus group Number a All Recurrences
shed by the immunized animals compared to control un-
Untreated 11/11 5.9 { 1.2 5.9 { 1.2immunized animals (Fig. 8). This difference increased to
Vaginal 6/9 1.8 { 0.8c 2.7 { 1.0100-fold and 1000-fold by Days 5 and 7, respectively.
Footpad ‘‘inactive’’ 3/14d 0.4 { 0.2e 1.7 { 0.7
Thus, parenteral immunization with 5BlacZ virus elicited Footpad ‘‘live’’ 2/15d 0.1 { 0.1e 1.0 { 0
protective immunity that reduced viral replication and/or
a Number of animals experiencing recurrences/number which couldspread at a mucosal site.
be evaluated.Protection against latent and recurrent infection. The
b Mean { SE. Recurrent lesion days between Day 15 and Day 42study of recurrent disease in the guinea pig model re-
postinoculation.
quires that animals recover from the primary infection c P  0.01 by ANOVA with Bonferroni correction.
well enough to be used to score recurrent infections. To d P  0.0005 by Fisher’s exact test.
e P  0.001 by ANOVA with Bonferroni correction.ensure an adequate number of animals for evaluation of
AID VY 8564 / 6a34$$$401 04-28-97 21:54:10 viral AP: Virology
10 DA COSTA ET AL.
reduced significantly by footpad or vaginal immunization normal inhibition of host cell DNA synthesis; therefore,
ICP8 is not required for this effect of the virus. HSV ICP8(Table 5). For all parameters of challenge virus infection,
live virus provided better protection than inactivated vi- is required for the redistribution of sites of host cell DNA
synthesis in the nuclei of infected cells (de Bruyn Kopsrus. The protection against recurrent disease afforded to
animals immunized with 5BlacZ was significant com- and Knipe, 1988). Thus, the redistribution of host cell
DNA synthesis sites and the inhibition of host cell DNApared to untreated controls (Table 5). Fewer of the immu-
nized animals developed recurrent lesions, and among synthesis appear to be separate effects of HSV infection
on the host cell. Consistent with the host cell shut-offthose that did, a significant reduction in the frequency of
recurrence during the period of evaluation was observed properties of the 5BlacZ mutant, cells infected with this
mutant showed CPE similar to that of cells infected withcompared to control animals. Thus immunization with
5BlacZ provided significant protection against primary wt virus as well as similar kinetics of loss of viability.
This indicates that although 5BlacZ does not replicateand recurrent infection, and live virus provided better
protection than killed virus. its DNA, it completes enough of the replicative cycle to
cause cell death. It is unlikely that any significant amount
of 5BlacZ will spread to sensory neurons to establish aDISCUSSION
latent infection (Katz et al., 1990). The implication of these
considerations is that, in host organisms immunized withWe have constructed and characterized a replication-
defective HSV-2 mutant and shown it to protect against 5BlacZ, infected cells will not survive and 5BlacZ is not
likely to persist in the host after inoculation of this virusgenital herpes in a guinea pig model of HSV-2 disease.
The virus has a mutation in an essential early gene, ICP8, for immunization. Experiments are in progress to mea-
sure the ability of HSV-2 replication-defective mutants toand grows only on cells that express functional ICP8. In
normal cells infected with this HSV-2 ICP8 mutant virus, establish latent infection.
The immunization studies in this report were designedexpression of IE, E, and at least some L genes occurs
although there is no viral DNA replication. In the absence to provide an initial test of the feasibility of using the
5BlacZ mutant virus to elicit protective immunity againstof viral DNA replication, 5BlacZ can express significant
levels of the late proteins ICP5, ICP15, and ICP25 and genital herpes infection in the guinea pig model. Immuni-
zation with one dose of 5BlacZ did reduce the incidencethe glycoproteins gB and gD. Previous studies have
shown that HSV-1 ICP8 not only serves as an essential and severity of genital disease and the shedding of virus
from primary infection of the genital tract. Immunizationcomponent of the viral DNA replication apparatus but
also is involved in the regulation of viral gene expression. did not prevent infection by the challenge virus in that
virus shedding was the same for immunized and unim-Specifically, HSV-1 ICP8 plays a role in repressing late
gene expression from parental genomes while stimulat- munized animals on Day 1. Thus, immunization with the
mutant virus reduced disease and virus spread, and fur-ing late gene expression from progeny genomes (Chen
and Knipe, 1996; Gao and Knipe, 1991; Godowski and ther studies are needed to optimize the dose and fre-
quency to further increase the protection against primaryKnipe, 1985). The regulatory effects exerted by ICP8 are
independent of its role in DNA synthesis; therefore, ICP8 infection. A second experiment to measure protection
against recurrent infection involved two immunizationsmutants showed altered gene expression compared to
wild-type virus in the presence of a viral DNA synthesis with 5BlacZ and challenge with a less virulent stock of
HSV-2. This showed better protection against primaryinhibitor. The ICP8 mutation in HSV-2 resulted in a similar
phenotype to that observed for HSV-1 ICP8 mutant vi- disease, probably due to the increased number of immu-
nizations. These immunized animals showed decreasedruses. The HSV-2 5BlacZ mutant virus was unable to
replicate its DNA and demonstrated altered gene expres- recurrent infections compared to the control animals, in-
dicating that immune effector mechanisms are acting tosion compared to wild-type virus or the rescued strain
5BR. Based on these observations, it appears that ICP8 decrease establishment of latent infection or reactivation
or both. Studies of immune protection against establish-exerts similar effects on gene expression in both HSV-1
and HSV-2. The similarity in the functions of HSV-1 and ment of latent infection by HSV-1 in murine trigeminal
ganglia have shown that CD4/ T cells play a major roleHSV-2 ICP8 is reinforced by the ability of the HSV-1 ICP8
expressed by the S2 cell line to complement the growth in protection from latent infection (Morrison and Knipe,
manuscript in preparation), but little is known about im-of the HSV-2 mutant virus. Growth of 5BlacZ in S2 cells
has the potential for rescue of the mutant virus by recom- mune mechanisms protecting against latent infection by
HSV-2. Further studies are needed to define the stagebination with the resident HSV-1 ICP8 gene in the S2 cell
line. Nevertheless, although the HSV-1 ICP8 gene can of HSV-2 infection or reactivation blocked by the host
immune response and the necessary components of thatfunctionally complement the defect in HSV-2 virus, the
HSV-2 genome and the HSV-1 gene do not readily recom- response.
One of the primary concerns about any live-virus vac-bine with each other as evidenced by the absence of
detectable wild-type recombinants (3 1 1007). cine must be safety. Live attenuated HSV-2 strains have
given some viral disease in animal models (McDermottThe ICP8 mutant studied in this work showed nearly
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Fuller, S. A., Takahashi, M., and Jurrell, J. G. R. (1995). In ‘‘Current Proto-et al., 1984; Stanberry et al., 1985b), raising concerns
cols in Molecular Biology’’ (F. M. Ausubel, R. Brent, R. E. Kingston,about their safety. The 5BlacZ mutant virus has elicited
D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl, Eds.), pp.
no disease in inoculated guinea pigs (Bourne and Stan- 11.5.1–11.5.3. Wiley, New York.
berry, unpublished results), immunocompetent mice, or Gao, M., and Knipe, D. M. (1989). Genetic evidence for multiple nuclear
functions of the herpes simplex virus ICP8 DNA-binding protein. J.even immunodeficient mice (Morrison, Da Costa, and
Virol. 63(12), 5258–5267.Knipe, unpublished results). Thus, although additional
Gao, M., and Knipe, D. M. (1991). Potential role for herpes simplex virusmutations need to be incorporated into any potential rep-
ICP8 DNA replication protein in stimulation of late gene expression.
lication-defective HSV-2 mutant strain for vaccine pur- J. Virol. 65(5), 2666–2675.
poses (Knipe et al., 1996) and further testing needs to be Ghiasi, H., Cai, S., Slanina, S., Nesburn, a. B., and Wechsler, S. L. (1995).
Vaccination of mice with herpes simplex virus type 1 glycoprotein Dperformed, these initial results indicate that a replication-
DNA produces low levels of protection against lethal HSV-1 chal-defective HSV-2 strain may show a high level of safety.
lenge. Antiviral Res. 28, 147–157.It is worth noting that parenteral immunization with
Godowski, P. J., and Knipe, D. M. (1985). Identification of a herpes sim-
5BlacZ was used to elicit protection against a mucosal plex virus function that represses late gene expression from parental
challenge. Optimal mucosal immunity is believed to re- viral genomes. J. Virol. 55(2), 357–365.
Godowski, P. J., and Knipe, D. M. (1986). Transcriptional control of her-quire mucosal immunization; thus, it will be important to
pesvirus gene expression: Gene functions required for positive anddetermine the mechanism(s) of the immunity elicited by
negative regulation. Proc. Natl. Acad. Sci. USA 83(2), 256–260.parenteral immunization as well as whether mucosal im-
Graham, F. L., and Van der Eb, A. J. (1973). A new technique for the
munization can increase the protection against a muco- assay of infectivity of human adenovirus 5 DNA. Virology 52, 456–
sal challenge. 457.
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